Adenovirus-vectored T cell vaccine for hepacivirus shows reduced effectiveness against a CD8 T cell escape variant in rats

Alex S. Hartlage1,2, Piyush Dravid1, Christopher M. Walker1,3, Amit Kapoor1,3*

1 Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, Ohio, United States of America, 2 Medical Scientist Training Program, College of Medicine and Public Health, The Ohio State University, Columbus, Ohio, United States of America, 3 Department of Pediatrics, College of Medicine and Public Health, The Ohio State University, Columbus, Ohio, United States of America

* amit.kapoor@nationwidechildrens.org

Abstract

There is an urgent need for a vaccine to prevent chronic infection by hepatitis C virus (HCV) and its many genetic variants. The first human vaccine trial, using recombinant viral vectors that stimulate pan-genotypic T cell responses against HCV non-structural proteins, failed to demonstrate efficacy despite significant preclinical promise. Understanding the factors that govern HCV T cell vaccine success is necessary for design of improved immunization strategies. Using a rat model of chronic rodent hepacivirus (RHV) infection, we assessed the impact of antigenic variation and immune escape upon success of a conceptually analogous RHV T cell vaccine. Naïve Lewis rats were vaccinated with a recombinant human adenovirus expressing RHV non-structural proteins (NS)3-5B and later challenged with a viral variant containing immune escape mutations within major histocompatibility complex (MHC) class I-restricted epitopes (escape virus). Whereas 7 of 11 (64%) rats cleared infection caused by wild-type RHV, only 3 of 12 (25%) were protected against heterologous challenge with escape virus. Uncontrolled replication of escape virus was associated with durable CD8 T cell responses targeting escaped epitopes alone. In contrast, clearance of escape virus correlated with CD4 T cell helper immunity and maintenance of CD8 T cell responses against intact viral epitopes. Interestingly, clearance of wild-type RHV infection after vaccination conferred enhanced protection against secondary challenge with escape virus. These results demonstrate that the efficacy of an RHV T cell vaccine is reduced when challenge virus contains escape mutations within MHC class I-restricted epitopes and that failure to sustain CD8 T cell responses against intact epitopes likely underlies immune failure in this setting. Further investigation of the immune responses that yield protection against diverse RHV challenges in this model may facilitate design of broadly effective HCV vaccines.
Author summary

The hepatitis C virus is one of the leading causes of chronic liver disease and cancer worldwide. A vaccine is not yet available and the first phase II clinical trial in humans using a T cell-based immunization strategy recently failed to prevent chronic infection in high risk individuals for unclear reasons. In this study we evaluated how immune escape mutations at major histocompatibility complex (MHC) class I-restricted viral epitopes influence the effectiveness of an adenoviral-vectorated T cell vaccine in a rat model of chronic HCV-related rodent hepacivirus infection, currently the only animal model available for evaluation of HCV vaccine strategies. We show that vaccine efficacy is markedly diminished when challenge virus contains naturally-acquired escape mutations at dominant MHC class I-restricted viral epitopes that render a subset of vaccine-generated CD8 T cell responses ineffective. We also identify CD4 T cell help as a critical correlate of vaccine success against heterologous virus challenge. Our results have important implications for human vaccination programs that aim to induce broad protective immunity against heterogeneous HCV strains.

Introduction

Hepatitis C virus (HCV) chronically infects 71 million people worldwide and contributes to 399,000 deaths annually[1]. Despite the advent of all oral, direct-acting antiviral (DAA) regimens that cure most infections, there are significant barriers to HCV eradication that necessitate development of a preventative vaccine. These include low rates of infection diagnosis, high cost of treatment, and emergence of drug-resistant strains[2,3]. In addition, DAA cure does not afford protective immunity against HCV reinfection[4], complicating the elimination of HCV within high-risk patient groups.

The first and only clinical trial to evaluate HCV vaccine efficacy in humans has recently concluded (NCT01436357). The investigational regimen consisted of sequential doses of chimpanzee adenoviral and modified vaccinia virus Ankara vaccines encoding HCV non-structural (NS) proteins, with a primary goal of inducing protective T cell immunity. Despite encouraging preclinical data[5,6] and a large body of evidence suggesting a critical role for T cells in immunity to HCV[7,8], no reduction in the overall incidence of chronic infection was observed[9]. Failure of this highly anticipated trial highlights a concerning gap in our understanding of protective immune responses to HCV and a need to identify factors that influence HCV vaccine efficacy.

A principal challenge for HCV vaccine development is overcoming the virus’ enormous genetic diversity[10]. HCV is composed of at least 7 major genotypes and more than 80 subtypes that differ considerably in amino acid sequence[11]. Additionally, the error-prone nature of HCV’s RNA-dependent RNA polymerase enables generation of diverse mutant progeny that can escape recognition by protective B and T cell responses[8]. This inter- and intra-strain diversity suggests that a broadly-reactive vaccine response will be necessary to protect against most if not all HCV variants. Indeed, a primary rationale for the selection of HCV NS proteins as a vaccine immunogen is their relative conservation amongst HCV strains. This property is reflected in the capacity for NS proteins from HCV genotype 1b to induce human T cell responses recognizing multiple heterologous strains[6]. Nevertheless, suboptimal recognition of infecting virus due to partial immunogen mismatch could significantly undermine the efficacy of an HCV vaccine.
Because of the NIH’s present moratorium on chimpanzee research, there are currently limited avenues to conduct mechanistic testing of candidate HCV vaccines. Recent discovery of an HCV-like rodent hepacivirus (RHV) in rats, however, has enabled development of a small animal challenge model[12–15]. The benefits of this surrogate system include ease of manipulation, immune competency, and high susceptibility to chronic infection. Although RHV differs substantially from HCV in amino acid sequence, similarities in genetic structure and organization, liver tropism, and DAA susceptibility make it highly relevant for HCV study [14,16,17]. Indeed, two recent studies, conducted in inbred and outbred rat strains, showed that recombinant adenoviral vectors encoding the RHV NS3-5B proteins reduce the incidence of persistent infection after homologous challenge[13,15]. Prolonged or persistent RHV infection after antibody-mediated depletion of CD8 or CD4 T cells, respectively, established a critical role for cellular immunity in vaccine protection[13]. Because natural variants of RHV have not yet been discovered, vaccine efficacy against infection by heterologous virus, particularly that which is mismatched at dominant T cell epitopes, is unknown.

In the present study we describe the generation of an RHV variant expressing immune escape mutations within major histocompatibility complex (MHC) class I-restricted epitopes that are dominant targets of CD8 T cell immunity in rats. Because this variant can approximate a heterologous challenge, we examined host-virus dynamics and protective immunity upon passage into rats immunized with a T cell-inducing adenoviral vector. Our findings have important relevance for HCV vaccine development and also provide unique insight into the role of mutational escape as a mechanism underlying hepacivirus persistence.

**Results**

**Vaccine selection of an RHV escape variant**

We recently demonstrated that vaccination of Lewis rats with a recombinant human adenovirus expressing the RHV NS3-5B proteins (Ad-NS; Fig 1A) confers partial protection against persistent infection[13]. In a single vaccinated rat (R558), breakthrough viremia following initial control of RHV infection coincided with emergence of non-synonymous mutations within two RT1-A\(^l\)-restricted class I epitopes (NS3\(_{974}\), NS4A\(_{1578}\)). A methionine to valine substitution at position 1581 (M1581V) resulted in diminished peptide recognition by NS4A\(_{1578}\)-specific CD8 T cells, indicating viral immune escape at this epitope[13]; escape at the NS3\(_{974}\) epitope was not confirmed. Since non-synonymous evolution of RHV class I epitopes does not occur after naive infection due to lack of functional CD8 T cell immunity[17], appearance of these mutations was a direct consequence of a vaccine-induced response.

Here, we provide an updated course of viremia for rat R558 along with complete polyprotein sequencing data. As initially reported[13], RHV viremia underwent large swings in magnitude (>10,000-fold) during days 7–21 post infection (p.i.) before reaching relatively stable titers (10\(^7\)–10\(^9\) genomes/mL) lasting >1 yr (Fig 1B). Direct PCR sequencing of rebound virus at day 14 p.i. following initial control of viremia revealed a total of 11 amino acid substitutions, most occurring within NS5A and a presumptive hypervariable region near the N-terminus of the E2 glycoprotein (Figs 1C and S1). The P981S and M1581V substitutions arising within NS3\(_{974}\) and NS4A\(_{1578}\) epitopes, respectively,[13] were confirmed (Fig 1D). The previously described F199L immune escape substitution occurring within the RT1-A\(^l\)-restricted E1\(_{191}\) epitope[17] was also found (Fig 1D); selection of this variant is particularly notable since envelope glycoproteins were not encoded by vaccine and cytokine-producing E1\(_{191}\)-specific CD8 T cells are not generated during naive infection[17]. This suggests that presence of vaccine-generated anti-NS3-5B immunity facilitated the functional maturation of anti-E1 responses that were primed by infection. Sequences of all other known RHV class I epitopes (Table 1) were
intact (Fig 1C). The functional significance of mutations occurring outside of class I epitope regions was not determined, but could be compensatory.

The F199L substitution persisted throughout chronic infection while the M1581V was replaced by a novel M1581L substitution at day 56 p.i. (Fig 1D), possibly due to enhanced in vivo viral fitness[18] or escape from de novo T cell responses generated against the mutated epitope. Presence of these substitutions at day 450 p.i. was associated with cytokine-producing CD8 T cells specific for the E1_{191} and NS4A_{1578} epitopes (Fig 1E). In contrast, the P981S substitution reverted to wild-type sequence by day 450 p.i. (Fig 1D), likely due to functional loss of NS3_{974}-specific CD8 T cells (Fig 1E) via exhaustion or deletion. Interestingly, stimulation with the dominant NS5B_{2511} epitope, which was intact throughout infection, failed to elicit a cytokine response (Fig 1E) despite moderate levels of tetramer-positive cells in liver (Fig 1F), which is consistent with a state of exhaustion driven by persistent antigenic stimulation.

Importantly, testing of wild-type and variant peptides in CD8 T cell recognition assays confirmed P981S and M1581L as immune escape substitutions (Fig 1G). These data suggest that vaccine failure in rat R558 was due, at least partially, to loss of immune recognition facilitated by selection of CD8 T cell escape mutants.
Reversion of CD8 T cell escape mutations after passage into naïve rats

To assess the stability of these immune escape substitutions in absence of strong CD8 T cell selection pressure, we passaged RHV recovered from R558 into two naïve rats. Circulating virus from day 21 p.i. (hereafter referred to as “escape virus”) was selected for transfer since at least three MHC class I epitopes were mutated at this timepoint (Fig 1B). High levels of viremia (~10^9 genomes/ml) were present by day 8 p.i. and persisted for several months without substantial change in magnitude (Fig 2A). Remarkably, all non-synonymous mutations were present at day 8 p.i., including those occurring outside of known RHV class I epitopes (Fig 2B and 2C). By day 60 p.i., the P981S and M1581V substitutions reverted to wild-type sequence, while all other non-synonymous changes, including the F199L substitution, remained (Fig 2B and 2C). Consistent with previous data[13,15,17], functional RHV-specific CD8 T cell responses were lacking at this timepoint (Fig 2D). Persistence of the F199L substitution without apparent immune pressure suggests that it does not confer a significant cost to in vivo viral fitness or is sufficiently stabilized by co-occurring compensatory mutations (Fig 2B). These data suggest that a strong RHV-specific CD8 T cell response is necessary to maintain the P981S and M1581V mutations within replicating escape virus.

Vaccine efficacy against escape virus

We next sought to determine whether virus containing the aforementioned escape mutations is less sensitive to a T cell-based vaccine expressing wild-type RHV antigen. We vaccinated rats with Ad-NS, which protects majority of animals from chronic infection following homologous challenge[13]. A booster dose was given after three weeks in an effort to enhance protective efficacy[15]. Three weeks after boosting rats were challenged with wild-type RHV or escape virus at equal dose. Consistent with prior findings[13], this regimen induced moderate frequencies of cytokine-producing CD8 T cells in liver (Fig 3A), with low levels of CD4 T cell help (Fig 3B). Overall, 7 of 11 (64%) rats challenged with wild-type RHV were protected.

| Polyprotein location | Amino acid sequence | MHC class I/II |
|----------------------|---------------------|----------------|
| E1 191-199           | SAFGTVARF           | I              |
| E2 439-456           | SAGWNLACYGQKGPLP   | I              |
| NS3 1294-1321        | SICVIGTPL           | I              |
| NS3 2299-1316        | IJQKGRHIFQTSKSHCDN | II             |
| NS3 1425-1442        | IVPDACIYEAFDSGLAYF | II             |
| NS3 1446-1463        | PAEVATHLSFYHQVL     | II             |
| NS1 488-498          | YVQSNYLEMKNRVDSTY  | II             |
| NS1 487-495          | YTYLAAQY           | I              |
| NS1 502-519          | AAYQYQLAKAGAMAPNDN | II             |
| NS4A 1578-1586       | CVFMAIDLF          | I              |
| NS4B 1747-1764       | MYGHAFTYGFATSLCV   | II             |
| NS5A 2248-2265       | MELLREYETSNDHVPPED | II             |
| NS5B 2486-2503       | SGKTEIVKTVLYSKEEGI | II             |
| NS5B 2511-2519       | CVMPKIEFF          | I              |
| NS5B 2525-2569       | VEKMLQGQPGTVKAVCD  | II             |
| NS5B 2559-2576       | QIGKPTVKGCGDAYGFV  | I              |

*Epitopes were identified in ref (13,17) and are RT1-A (class I) or RT1-B/D (class II) restricted according to the MHC background of Lewis rats

*Amino acid position according to the start of the RHV polyprotein (accession no. KX905133; protein cleavage sites predicted in ref (14)

https://doi.org/10.1371/journal.ppat.1009391.t001
against persistent infection after establishment of acute viremia (Fig 3C). As previously reported[13], viremia was terminated or underwent substantial decline during the first three weeks of acute resolving infection. In contrast, only 3 of 12 (25%) rats controlled infection caused by escape virus (Fig 3D, left panel). Importantly, clearance of escape virus in this group was not facilitated by reversion of variant class I epitopes to wild-type sequence (Fig 3D, right panel). In both challenge groups, acute non-resolving infection was characterized by stable high-level viremia (Fig 3C and 3D). Despite a clear trend towards diminished immunity against escape virus (64% vs 25%), the difference in infection outcome between challenge groups was marginally insignificant (Fig 3E; p = 0.0995). There was, however, a significant increase in peak viremia in rats challenged with escape virus (Fig 3F), indicating less effective control of viral replication.

T cell immunity and viral evolution during RHV persistence

To determine whether viral immune escape contributed to vaccine failure within each challenge group, we analyzed intrahepatic T cell responses and class I epitope sequences at time of study termination (day 84–91 p.i.). Despite no apparent difference in the course of chronic viremia between challenge groups (Fig 4A, left panel), there was considerable difference in the frequency of cytokine-producing CD8 T cells that recognized wild-type RHV antigens. Indeed, rats challenged with escape virus showed durable, high magnitude responses against a pool of class I and II epitopes (Table 1), whereas similar activity was lacking in the wild-type challenge group (Fig 4A, right panel). This apparent lack of T cell pressure within the wild-type challenge group was overall reflected at the viral sequencing level. The escape-prone NS3<sub>974</sub> and NS4A<sub>1578</sub> epitopes, which were targeted by vaccination, were intact in all animals (Fig 4B). The E1<sub>191</sub> epitope, by contrast, showed some diversification. Virus from a single rat contained the F199L substitution, while two others expressed a novel T196I variant; since these substitutions were not accompanied by strong CD8 T cell selection pressure similar to R558 (Fig 1D), it is possible that these mutations were driven by an anti-E1 antibody response or earlier T cell activity.
By comparison, class I epitope sequences in the escape virus challenge group were dynamic. The P981S substitution within NS3\(\text{974}\) reverted to wild-type in 4 of 9 (44.4%) rats and was replaced by one of four novel substitutions (V977I, I978V, T980S, P981T) in remaining animals (Fig 4C, left panel); these novel variants were confirmed as immune escape substitutions (Fig 4D). The M1581V substitution within NS4A\(\text{1578}\) was replaced by M1581L in 5 of 9 (55.6%) rats as originally occurred in R558 and reverted to wild-type sequence in all others (Fig 4C, left panel). Selection of new escape mutations in NS3\(\text{974}\) and NS4A\(\text{1578}\) was consistent with there being durable T cell pressure against these regions (Fig 4A, right panel). Similar to naïve passage, the F199L substitution persisted in all rats (Fig 4C) despite the lack of an E1\(\text{191}\) -specific functional response (Fig 4A, right panel). Overall, 7 of 9 (77.8%) rats were persistently infected with virus expressing non-synonymous mutations in either NS3\(\text{974}\) or NS4A\(\text{1578}\) that were not present in the escape virus inoculum (Fig 4C, right panel), suggesting continued viral evolution resulting from ongoing CD8 T cell selection pressure.

Taken together, these data strongly suggest that lack of control of escape virus in most rats was due to an inability to recognize mutated class I epitopes, particularly NS3\(\text{974}\) and NS4A\(\text{1578}\) that were targeted by vaccination. By contrast, persistence of wild-type virus was associated with overall absent T cell responses and no clear evidence of viral immune escape from vaccine-induced immunity.
Next, to identify immune mechanisms facilitating control of escape virus in minority of rats, we compared intrahepatic T cell responses between infection outcome groups (resolvers vs. non-resolvers) at day 84–91 post infection. No significant difference was found in the frequency of cytokine-producing CD8 T cells specific for the escape-prone NS3$_{974}$ or NS4A$_{1578}$ epitopes that were mutated in escape virus; responses against the E1$_{191}$ epitope were absent in both groups (Fig 5A), possibly due to failed priming by variant peptide. However, a significantly higher

Fig 4. T cell responses and viral evolution in infection non-resolvers. Vaccinated rats that failed to control wild-type or escape virus infection were analyzed for T cell immunity and viral mutations (E1$_{191}$, NS3$_{974}$, NS4A$_{1578}$) at day 84–91 post infection. (A) Left panel, course of RHV viremia. Limit of detection of RT-PCR assay was 1875 genomes/mL. Right panel, frequency of intrahepatic CD8 T cells producing IFNγ or TNFα (mean ± SEM) after 5-hr stimulation with pooled class I/II (5 µg/mL each; Table 1) or individual epitopes (10 µg/mL). Response was determined by intracellular cytokine staining assay. n.a., not assessed. (B) Epitope variant frequencies within wild-type challenge group. (C) Left panel, epitope variant frequencies within escape virus challenge group. Presence of wild-type epitope indicates sequence reversion. Consensus amino acid identities were determined by direct PCR or clonal sequencing. Right panel, venn diagram illustrating the proportion of rats with the indicated epitope variants. (D) Frequency of CD8 T cells from immune rat producing IFNγ or TNFα upon stimulation with titrated concentrations of wild-type or variant NS3$_{974}$ peptides.

https://doi.org/10.1371/journal.ppat.1009391.g004

T cell responses associated with protection against escape virus

Next, to identify immune mechanisms facilitating control of escape virus in minority of rats, we compared intrahepatic T cell responses between infection outcome groups (resolvers vs. non-resolvers) at day 84–91 p.i. No significant difference was found in the frequency of cytokine-producing CD8 T cells specific for the escape-prone NS3$_{974}$ or NS4A$_{1578}$ epitopes that were mutated in escape virus; responses against the E1$_{191}$ epitope were absent in both groups (Fig 5A), possibly due to failed priming by variant peptide. However, a significantly higher
frequency of cytokine-producing cells was found in resolvers following stimulation with a pool of peptides containing seven class I epitopes (Table 1 and Fig 5A), suggesting greater functional breadth. Further analysis of cryopreserved samples indeed revealed significant enrichment for CD8 T cells targeting the NS5B\textsubscript{2511} and, less strongly, NS3\textsubscript{1487} epitopes (Fig 5B). This preservation of CD8 T cell functionality against intact epitopes in resolvers was further accompanied by enhanced recall of RHV-specific CD4 T cell immunity (Fig 5C). These findings suggest that elimination of escape virus was related to the capacity to sustain CD8 T cell responses against intact epitopes, a feature possibly supported by presence of CD4 T cell help.

Resolution of wild-type RHV infection yields protective immunity to escape virus

Resolution of wild-type RHV infection appears to boost vaccine-induced CD4 T cell help and induce functional CD8 T cell responses to epitopes not encoded by adenoviral vaccine\cite{13,17}. This broadening and enhancement of RHV-specific immunity may confer protection against heterologous strains, as observed for HCV\cite{19,20}. We therefore tested whether rats that previously controlled wild-type RHV infection were protected against secondary challenge with escape virus. Expectedly, 6 of 7 (86%) rats were protected from persistent infection after experimental challenge (Fig 6A). All rats, except for a single aviremic animal, developed variable levels of viremia that were controlled by day 14 p.i. A single rat, however, developed breakthrough viremia at day 30 p.i. Despite this, the overall rate of protection was significantly increased compared to primary vaccine challenge (Fig 6B; 86% vs 25%). This finding demonstrates that, although vaccination with Ad-NS induces weak protection against escape virus, achieving a high level of protection is feasible in concept.

Discussion

Vaccination against HCV using T cell-based viral vectors targeting non-structural proteins recently failed to prevent chronic infection in a high-risk population of injection drug users \cite{9}. There is presently no explanation for why this trial failed, an urgent question given the strong preclinical data supporting its potential efficacy\cite{5,6,13,15,21}. Because of HCV’s extraordinary diversity, one plausible mechanism is insufficient genetic overlap between vaccine immunogen and the infecting HCV strain, hindering viral recognition by vaccine-
established T cell responses. Here, we directly evaluated this risk using the RHV rat model which closely mimics HCV infection and viral persistence.

Our results indicate that a virally-vectored RHV T cell vaccine, which is principally analogous to the human approach and generally efficacious[13], is less effective when challenge virus contains immune escape mutations that render it poorly recognizable to vaccine-elicited CD8 T cells. Importantly, these mutations arose naturally during persistent infection of rat R558 and thus had a high probability of disrupting immune protection in new vaccine recipients. Although not truly representative of the type of heterologous exposure events expected to occur after HCV vaccination, these results provide a conceptual approximation of what might ensue when vaccine-elicited CD8 T cell responses are effectively narrowed due to absence of recognizable epitopes in infecting virus. The major advantage of this work, in comparison to earlier chimpanzee studies assessing heterologous immunity conferred via T cell-based vaccines[5,22], is that viral persistence is a universal feature of rat RHV infection in absence of vaccination, enabling uncomplicated analysis of infection outcomes.

These data also provide insight into mutational escape as a causal mechanism of hepacivirus persistence. Persistence of acute HCV infections is strongly associated with emergence of escape mutations in dominant MHC class I epitopes in chimpanzees[23,24] and humans[25–27]. However, direct evidence to support CD8 T cell escape as a cause rather consequence of HCV persistence has been difficult to establish in absence of robust animal models with identical MHC backgrounds. Because the restricting RT1-A1 allele is conserved amongst the Lewis strain, we were able to directly address the impact of viral escape on infection outcome via passage of escape virus into uninfected individuals. The higher persistence rate of escape virus in vaccinated rats illustrates that these mutations do negatively influence vaccine control of infection. Similar results might be expected for HCV as well given similar experimental constraints.

It is necessary to acknowledge that, despite a sizable reduction in vaccine efficacy against escape virus, this difference was marginally insignificant in comparison to wild-type RHV challenge. Therefore, interpretation of our results should be tempered. However, several lines of evidence suggest that infection initiated by escape virus did indeed result in fundamentally altered patterns of RHV immunity and viral persistence. First, there was overall weaker control of infection initiated by escape virus as illustrated by significantly increased peak viremia irrespective of outcome. This was presumably due to poorer viral recognition by vaccine-established CD8 T cell responses. Second, failure to eliminate escape virus was associated with durable CD8 T cell responses targeting escape-prone epitopes, specifically NS3974 and NS41578 that were targeted by vaccine. These responses were actively maintaining viral variation at these epitopes, as evidenced by emergence of novel escape substitutions. It is unclear whether these mutations emerged as a consequence of viral evolution to more a fit state[28] or because de novo T cell responses specific to the original escape variant were generated[29]. Regardless of the reason, a similar phenomenon was absent from rats that failed to control wild-type RHV infection, suggesting a predominantly different mechanism of vaccine failure (e.g. immune exhaustion) in this specific challenge setting.

Our results also shed light on the immune responses required to control a heterologous infection. Indeed, we found that vaccine-mediated clearance of escape virus, although infrequent, significantly correlated with sustained CD8 T cell cytokine activity against intact epitopes in NS3 and, in particular, NS5B. These responses were absent from persistently infected rats despite similar levels of functional CD8 T cells specific to escaped epitopes. Since CD8 T cell immunity was not assessed prior to infection, it is conceivable that responses to intact epitopes were not adequately primed by vaccine in these animals, thus permitting uncontrolled viral replication. However, given the strong CD8 T cell-inducing potential of the adenovirus vector utilized here, a more plausible scenario is that vaccine responses were deleted and/or
became functionally exhausted during progression to persistent infection as is typical of HCV [7]. Indeed, acquisition and later reversion of the P981S escape mutation in virus from rat R558 suggests that relaxation of virus-specific CD8 T cell immunity can occur during RHV persistence. Because CD8 T cells are required for vaccine clearance of RHV infection[13], it is highly likely that maintenance of responses to intact epitopes was a cause rather than consequence of viral elimination. How these responses were preserved is not yet clear, but their association with CD4 T cell help suggests that this interaction may be pivotal. During acute HCV infections, maintenance of an effective CD4 T helper response is a strong determinant of viral clearance[30–32], and loss of this subset is thought to underlie impaired control by HCV-specific CD8 T cells[33]. Viral silencing or inadequate priming of RHV-specific CD4 T cells by vaccine may thus ultimately drive persistence of escape virus. Indeed, in an earlier study evaluating a T cell-based vaccine in chimpanzees, control of heterologous HCV infection correlated with the quality of vaccine-elicited T helper immunity[22]. The recombinant human adenovirus vector utilized here is considered a poor inducer of CD4 T cell help[34] and, in a setting where CD8 T cells are already strained due to reduced recognition of virus, this factor may significantly undercut vaccine efficacy. Consequently, two potential solutions to improving vaccine efficacy in this model include increasing T cell breadth by inclusion of additional viral proteins (e.g. E1/E2) and bolstering CD4 T cell immunity via boosting with a heterologous viral vector such as MVA[21].

Vaccinated rats that previously controlled antigen-matched RHV infection were fully protected against secondary challenge with escape virus, except for a single animal that developed breakthrough viremia. The rate of protection exceeded that provided by vaccination alone, indicating a significant enhancement of RHV immunity not unlike that observed after spontaneous resolution of acute HCV infections in naïve subjects[35,36]. This effect could have been mediated by generation of de novo T cell responses specific to non-vaccine encoded antigens such as structural proteins[17] and/or qualitative enhancement of existing T cells that conferred lasting reactivity to intact epitopes. Indeed, inclusion of structural proteins has been implicated in improved RHV[15] and HCV vaccine efficacy[15]. An additional possibility is stimulation of an anti-E1/E2 neutralizing antibody response that helped suppress RHV viremia prior to T cell compromise. Investigation of the immune mechanisms that underlie this improved protection could provide a novel blueprint for inducing broadly effective HCV immunity.

Prior studies of HCV in humans suggest that unfit CD8 T cell escape mutations will revert under settings of reduced or absent selection pressure. This has been described after transmission into recipients mismatched at the restricting MHC allele[25,37,38] and following the immunoregulatory changes associated with pregnancy[18]. Stable reversion of RHV escape mutations in two different RT1-A*-restricted epitopes following passage into naïve rats provides a unique example of this phenomenon occurring in immune-competent, MHC-matched recipients. For reasons that have yet to be explained, RHV-specific CD8 T cells are severely dysfunctional during infection of naïve rats and consequently do not apply selective pressure against persistent virus[13,17]. Uniquely, emergence of RHV escape mutations has only been described when CD8 T cell pressure is induced via vaccine[13,15] or following acute antiviral treatment with DAA[17]. Interestingly, loss of the F199L substitution was not observed after virus passage, so reversion of RHV escape mutations to their ancestral state is not assured in every case. It will be interesting to determine in future studies whether and how new mutations acquired via serial passage of escape virus in vaccinated rats acquire lasting stability.

In conclusion, our results reveal antigen mismatch as an important determinant of RHV T cell vaccine success. Since HCV possesses a high degree of genetic variability, this factor may substantially weaken the efficacy of analogous vaccination approaches in humans. Further
understanding of the mechanisms that facilitate heterologous RHV immunity, which appears possible, may have important implications for development of broadly effective HCV vaccines in humans, where similar studies are difficult to pursue.

Materials and methods

Ethics statement

All biohazard and animal experiments were carried out in accordance with approved protocols from the Nationwide Children’s Research Institute Institutional Biosafety Committee (protocol number IBS00000285) and the Institutional Animal Care and Use Committee (protocol number AR15-00116), respectively.

Animals

Male and female Lewis rats were obtained from Charles Rivers Laboratories and bred under standard protocol. Rats were 6–9 weeks of age at time of study. All animal experiments were approved by the Institutional Animal Care and Use Committee by the Abigail Wexner Research Institute prior to initiation.

Viruses and infections

The wild-type RHV inoculum was derived in vivo from a consensus genomic clone as described[14]. The escape variant described herein was isolated from a single vaccinated rat that developed persistent infection coincident with mutations in defined class I epitope sequences. For all infections, rats were challenged intravenously via tail vein with $10^6$ viral genomes.

Virus quantification

RHV titers were determined exactly as described[13] with the lone modification that serum viral RNA was extracted using the Quick-RNA viral kit (ZYMO RESEARCH). In brief, viral cDNA was generated from serum extracted RNA using the GoScript reverse transcription kit (Promega) with random hexamer priming, followed by quantification on a StepOnePlus RT-PCR system (Applied Biosystems) using the PowerUP SYBR green master mix (Applied Biosystems). A standard curve was generated using a linearized plasmid encoding the RHV NS3 protein. The limit of detection of viral RNA was determined to be 1875 genomes/mL serum.

Viral polyprotein sequencing

Overlapping PCR fragments spanning the entire RHV polyprotein coding sequence were amplified from viral cDNA using the Q5 High-Fidelity Polymerase (New England Biolabs) and directly sequenced (Eurofins Genomics) using nested sequencing primers. All non-synonymous changes in the consensus polyprotein sequence (accession no. KX905133) were analyzed for occurrence of mixed sequencing peaks and noted in the amino acid sequence where possible. The mixed I978V/T980S quasispecies variant was confirmed by standard clonal sequencing using the pGEM®-T easy vector (Promega). All primer sequences used are listed in Table 2.

Vaccinations

The recombinant human adenovirus serotype 5 vector expressing the RHV NS3-5B protein (Ad-NS) under control of a high-expression CMV promotor has been described[13]. Notably,
the GDD catalytic site of the NS5B RNA polymerase was mutated to GNN to disrupt in vivo replication activity. The vector was generated and titrated by Vector Biolabs. Rats received two intramuscular doses of Ad-NS (5 x 10^8 infectious units) separated three weeks apart. Three weeks after booster injection, rats were challenged with wild-type or escape virus.

**Peptides**

All peptides were obtained from Genemed Synthesis as a lyophilized powder. 10 mg/mL stock solutions were prepared in a 10% DMSO-water solution and stored at -80˚ C until use. The final concentration of each peptide in all functional assays was 5 or 10 μg/mL unless otherwise specified.

**Leukocyte isolation, culture, and cryopreservation**

Isolation and culture of liver-infiltrating leukocytes was performed exactly as described[13]. In brief, PBS-perfused livers were gently homogenized through a stainless-steel mesh in PBS supplemented with 2.5% FBS (Gibco). Cells were then isolated via 37% Percoll (GE Life Sciences) gradient density centrifugation at 500 x g for 20 min followed by lysis of residual RBCs in ACK buffer (Gibco). For cytokine stimulation assays described below, cells were cultured in RPMI-

---

Table 2. RHV primer sequences.

| Name          | Sequence (5’➔3’) | Name          | Sequence (5’➔3’) |
|---------------|-----------------|---------------|-----------------|
| C-NS2-1-F1    | CGAGGGGTTCGCCCTGTAAC | NS34-4-F1     | GCTTGAGGGGCGCTTC |
| C-NS2-1-F2    | CGAGGGGTTCGCCCTGTAACC | NS34-4-F2     | CTTGAGGGGCGCTTCAGG |
| C-NS2-1-R1    | CACCTCGTCAGAGGCTGACA | NS34-4-R1     | GCAGCCCCAAAGACACG |
| C-NS2-1-R2    | CTGTCGTCAGAGGCTGACAGG | NS34-4-R2     | CCCAAAGACACAGCCCG |
| C-NS2-2-F1    | CTGACGTAGCTTCTCGCTAGT | NS34-5-F1     | AGCTCGCTGCCCTTCCT |
| C-NS2-2-F2    | CTCGACCCTGCTTCTCTTC | NS34-5-F2     | CTCGCTGCTCCCCTCTCC |
| C-NS2-2-R1    | CAGTTGTAGCAGGGGCTGAGT | NS34-5-R1     | CACACAGCATCTGCAAC |
| C-NS2-2-R2    | GCCAGGGGTAGTGCACACACA | NS34-5-R2     | CACACAGCATCTGCAAC |
| C-NS3-3-F1    | GCTACACTGTGGGAGGCCCTT | NS34-5-R1     | CCGATACAAGGGGACCTTG |
| C-NS3-3-F2    | CATACACTGTGGGAGGCCCTG | NS34-5-F2     | CCGATACAAGGGGACCTTG |
| C-NS3-3-R1    | GCCAATACAGAGAAGCTCCC | NS34-5-R1     | CCAATCTGACTGACCA |
| C-NS3-3-R2    | GCCAAGATCAGAAGAGCTCCAGC | NS34-5-R2     | CCAATCTGACTGACCA |
| C-NS3-4-F1    | AGCGCTAGCAGGGGCCG | NS34-5-F1     | CCGTACCAGCACAGCAG |
| C-NS3-4-F2    | AGGCTTACGAGGGGCTGTA | NS34-5-F2     | CCGTACCAGCACAGCAG |
| C-NS3-4-R1    | GAAAGGCTGACAGGGGCTG | NS34-5-F2     | CCGTACCAGCACAGCAG |
| C-NS3-4-R2    | AGCGCTAGCAGGGGCTG | NS34-5-F2     | CCGTACCAGCACAGCAG |
| NS34-1-F1     | GACATCCAGCTTCTGAGG | NS34-5-F1     | CCGTACCAGCACAGCAG |
| NS34-1-F2     | GACGTAGCAGGGGCTG | NS34-5-F1     | CCGTACCAGCACAGCAG |
| NS34-1-R1     | GAGCTAGCCAGATCTGGG | NS34-5-R1     | CAGGTACCAGCACAGCAG |
| NS34-1-R2     | AGCGCTAGCAGGGGCTG | NS34-5-R1     | CAGGTACCAGCACAGCAG |
| NS34-2-F1     | GACGTAGCAGGGGCTG | NS34-5-R1     | CAGGTACCAGCACAGCAG |
| NS34-2-F2     | AGCGCTAGCAGGGGCTG | NS34-5-R1     | CAGGTACCAGCACAGCAG |
| NS34-2-R1     | GACGTAGCAGGGGCTG | NS34-5-R1     | CAGGTACCAGCACAGCAG |
| NS34-2-R2     | AGCGCTAGCAGGGGCTG | NS34-5-R1     | CAGGTACCAGCACAGCAG |
| NS34-3-F1     | AGCGCTAGCAGGGGCTG | NS34-5-R1     | CAGGTACCAGCACAGCAG |
| NS34-3-F2     | AGCGCTAGCAGGGGCTG | NS34-5-R1     | CAGGTACCAGCACAGCAG |
| NS34-3-R1     | AGCGCTAGCAGGGGCTG | NS34-5-R1     | CAGGTACCAGCACAGCAG |
| NS34-3-R2     | AGCGCTAGCAGGGGCTG | NS34-5-R1     | CAGGTACCAGCACAGCAG |

https://doi.org/10.1371/journal.ppat.1009391.t002

the GDD catalytic site of the NS5B RNA polymerase was mutated to GNN to disrupt in vivo replication activity. The vector was generated and titrated by Vector Biolabs. Rats received two intramuscular doses of Ad-NS (5 x 10^8 infectious units) separated three weeks apart. Three weeks after booster injection, rats were challenged with wild-type or escape virus.

**Peptides**

All peptides were obtained from Genemed Synthesis as a lyophilized powder. 10 mg/mL stock solutions were prepared in a 10% DMSO-water solution and stored at -80˚ C until use. The final concentration of each peptide in all functional assays was 5 or 10 μg/mL unless otherwise specified.

**Leukocyte isolation, culture, and cryopreservation**

Isolation and culture of liver-infiltrating leukocytes was performed exactly as described[13]. In brief, PBS-perfused livers were gently homogenized through a stainless-steel mesh in PBS supplemented with 2.5% FBS (Gibco). Cells were then isolated via 37% Percoll (GE Life Sciences) gradient density centrifugation at 500 x g for 20 min followed by lysis of residual RBCs in ACK buffer (Gibco). For cytokine stimulation assays described below, cells were cultured in RPMI-
1640 containing GlutaMAX and HEPES (Gibco), 10% FBS (Gibco), 50 U/mL penicillin-streptomycin (Gibco), and 55 μM 2-mercaptoethanol (Gibco) at 37˚ C. For storage, cells were cryopreserved in FBS containing 10% DMSO via standard protocol.

**Antibodies and flow cytometry**

The following rat reactive antibodies (clone, staining dilution) were obtained from BD Biosciences, eBioscience, and Miltenyi Biotec for use in flow cytometric analysis: CD3-VioGreen (REA223, 1:300), CD3-BV421 (IF4, 1:200), CD4-PerCP-eFluor710 (OX35, 1:250), CD8-BV786 (OX8, 1:100), IFNγ-AF647 (DB-1, 1:100), IFNγ-eFluor660 (DB-1, 1:50), TNFα-FITC (TN3-19.12, 1:50), and TNFα-PE (TN3-19.12, 1:100). Surface stains were performed for 20 min at 4˚ C in 50 μL PBS supplemented with 2.5% FBS (Gibco) and 0.1% sodium azide (Sigma Aldrich) in 96-well U-bottom plate. Dead cells were excluded from analysis using the LIVE/DEAD nearIR dye (Invitrogen) per manufacturer’s protocol. Events were collected on a BD Fortessa flow cytometer following compensation with UltraComp eBeads (Invitrogen). Data were analyzed using FlowJo v7.6.5 (Tree Star).

**Intracellular cytokine analysis**

Quantification of T cell cytokine production by intracellular staining was performed as described[13]. In brief, 10⁶ cells were stimulated in a single well of a 96-well U-bottom plate with peptide for 5-hr in the presence of brefeldin-A, followed by intracellular cytokine staining using the Cytofix/Cytoperm kit (BD Biosciences). Stimulation with no peptide and PMA + Ionomycin (BioLegend) were used as negative and positive controls, respectively. Response magnitude was calculated by subtracting the frequency of cytokine positive cells in negative control from that of experimental samples. A positive response was defined as ≥3 times background staining prior normalization.

**Tetramer staining**

Biotinylated rat RT1-A¹ monomers specific for the RHV E1₁₉₁ and NS5B₂₅₁₁ epitopes were obtained from the NIH Tetramer Core Facility and tetramerized with streptavidin-APC (Prozyme) via standard protocol. For direct detection of virus-specific CD8 T cell populations, liver-infiltrating leukocytes were stained for 30 min at 4˚ C (1:100) with tetramer alone followed by surface labeling with anti-rat CD3 and CD8 as above. Following staining with LIVE/DEAD near IR dye (Invitrogen), cells were fixed in 1% PFA prior to analysis.

**Statistics**

Differences in vaccine outcome were assessed for significance using Fisher’s exact test. Differences in T cell immunity were assessed for significance using Student’s t-test with unequal variance.

**Supporting information**

S1 Fig. Evolution of RHV polyprotein in vaccinated rat R558. Overlapping PCR fragments spanning the complete RHV coding segment were amplified by a high-fidelity polymerase and directly sequenced. Consensus amino acid substitutions are shown. Shaded sequences mark location of known RT1-A¹-restricted class I epitopes. Multiple sequencing peaks were resolved where possible into mixed amino acid residues.

(DOCX)
Acknowledgments

We thank the NIH Tetramer Core Facility for developing the tetramer technology used in this study.

Author Contributions

Conceptualization: Alex S. Hartlage, Amit Kapoor.

Data curation: Alex S. Hartlage, Piyush Dravid, Amit Kapoor.

Formal analysis: Alex S. Hartlage, Piyush Dravid, Amit Kapoor.

Funding acquisition: Alex S. Hartlage, Amit Kapoor.

Investigation: Alex S. Hartlage, Christopher M. Walker, Amit Kapoor.

Methodology: Alex S. Hartlage, Piyush Dravid, Christopher M. Walker, Amit Kapoor.

Project administration: Amit Kapoor.

Resources: Christopher M. Walker, Amit Kapoor.

Supervision: Amit Kapoor.

Validation: Alex S. Hartlage, Amit Kapoor.

Visualization: Alex S. Hartlage, Amit Kapoor.

Writing – original draft: Alex S. Hartlage, Amit Kapoor.

Writing – review & editing: Alex S. Hartlage, Piyush Dravid, Christopher M. Walker, Amit Kapoor.

References

1. Westbrook RH, Dusheiko G. Natural history of hepatitis C. Journal of hepatology. 2014; 61(1 Suppl): S58–68. https://doi.org/10.1016/j.jhep.2014.07.012 PMID: 25443346

2. Konerman MA, Lok AS. Hepatitis C Treatment and Barriers to Eradication. Clinical and translational gastroenterology. 2016; 7(9):e193. https://doi.org/10.1038/ctg.2016.50 PMID: 27657495

3. Bartenschlager R, Baumert TF, Bukh J, Houghton M, Lemon SM, Lindenbach BD, et al. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Res. 2018; 248:53–62. https://doi.org/10.1016/j.virusres.2018.02.016 PMID: 29477699

4. Rossi C, Butt ZA, Wong S, Buxton J, Islam N, Yu A, et al. Hepatitis C Virus Reinfection after Successful Treatment with Direct-Acting Antiviral Therapy in a Large Population-Based Cohort. Hepatology. 2018; 68:907a–a.

5. Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med. 2006; 12(2):190–7. https://doi.org/10.1038/nm1355 PMID: 16462801

6. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Science translational medicine. 2012; 4(115):115ra1. https://doi.org/10.1126/scitranslmed.3003155 PMID: 22218690

7. Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. Journal of hepatology. 2014; 61:S14–S25. https://doi.org/10.1016/j.jhep.2014.06.035 PMID: 25443342

8. Walker CM. Adaptive immunity to the hepatitis C virus. Adv Virus Res. 2010; 78:43–86. https://doi.org/10.1016/B978-0-12-385032-4.00002-1 PMID: 21040831

9. Cox AL, Page K, Melia M, Veenhuis R, Massaccesi G, Osburn W, et al. LB10. A Randomized, Double-Blind, Placebo-Controlled Efficacy Trial of a Vaccine to Prevent Chronic Hepatitis C Virus Infection in an at-Risk Population. Open forum infectious diseases. 2019; 6(Supplement_2):S997–S.
10. Bailey JR, Barnes E, Cox AL. Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. Gastroenterology. 2019; 156(2):418–30. https://doi.org/10.1053/j.gastro.2018.08.060 PMID: 30268785

11. Smith DB, Bukh J, Kuiken C, Muñoz-Fernández AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology. 2014; 59(1):318–27. https://doi.org/10.1002/hep.26744 PMID: 24115039

12. Firth C, Bhat M, Firth MA, Williams SH, Frye MJ, Simmonds P, et al. Detection of zoonotic pathogens and characterization of novel viruses carried by commensal Rattus norvegicus in New York City. MBio. 2014; 5(5):e01933–14. https://doi.org/10.1128/mBio.01933-14 PMID: 25316698

13. Hartlage AS, Murthy S, Kumar A, Trivedi S, Dravid P, Sharma H, et al. Vaccination to prevent T cell subversion can protect against persistent hepatitis C virus. Nat Commun. 2019; 10(1):1113. https://doi.org/10.1038/s41467-019-09105-0 PMID: 30846697

14. Trivedi S, Murthy S, Sharma H, Hartlage AS, Kumar A, Gadi S, et al. Survival, persistence, liver disease and host response in Hepatitis C-like virus rat model. Hepatology. 2017.

15. Atcheson E, Li WQ, Bliss CM, Chinnakannan S, Heim K, Sharpe H, et al. Use of an Outbred Rat Hepatitis C Virus Challenge Model for Design and Evaluation of Efficacy of Different Immunization Strategies for Hepatitis C Virus. Hepatology. 2019. https://doi.org/10.1002/hep.30894 PMID: 31400152

16. Wolfsberg R, Holmbeck K, Nielsen L, Kapoor A, Rice CM, Bukh J, et al. Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells. Journal of Virology. 2019; 93(19). https://doi.org/10.1128/JVI.00733-19 PMID: 31292246

17. Hartlage AS, Walker CM, Kapoor A. Priming of Antiviral CD8 T Cells without Effector Function by a Persistently Replicating Hepatitis C-Like Virus. J Virol. 2020; 94(10). https://doi.org/10.1128/JVI.00035-20 PMID: 32102885

18. Honegger JR, Kim S, Price AA, Kohout JA, McKnight KL, Prasad MR, et al. Loss of immune escape mutations during persistent HCV infection in pregnancy enhances replication of vertically transmitted viruses. Nat Med. 2013; 19(11):1529–33. https://doi.org/10.1038/nm.3351 PMID: 24196214

19. Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, et al. Cross-genotype immunity to hepatitis C virus. J Virol. 2004; 78(3):1575–81. https://doi.org/10.1128/jvi.78.3.1575-1581.2004 PMID: 14722311

20. Prince AM, Brotman B, Lee DH, Pfahler W, Tricoche N, Andrus L, et al. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. The Journal of infectious diseases. 2005; 192(10):1701–9. https://doi.org/10.1086/496889 PMID: 16235167

21. Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Science translational medicine. 2014; 6(261):261ra153. https://doi.org/10.1126/scitranslmed.3009185 PMID: 25378645

22. Rollier C, Depla E, Dreuxhage JA, Verschoor EJ, Verstrepen BE, Fatmi A, et al. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J Virol. 2004; 78(1):187–96. https://doi.org/10.1128/jvi.78.1.187-196.2004 PMID: 14671100

23. Weiner A, Erickson AL, Kansopon J, Crawford K, Muchmore E, Hughes AL, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A. 1995; 92(7):2755–9. https://doi.org/10.1073/pnas.92.7.2755 PMID: 7708719

24. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity. 2001; 15(6):883–95. https://doi.org/10.1016/s1074-7613(01)00245-x PMID: 11754811

25. Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, Lucas M, et al. CD8 epitope escape and reversion in acute HCV infection. The Journal of experimental medicine. 2004; 200(12):1593–604. https://doi.org/10.1084/jem.20041006 PMID: 15611288

26. Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, Lewinsohn DM, et al. Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. The Journal of experimental medicine. 2005; 201(11):1725–31. https://doi.org/10.1084/jem.20042284 PMID: 15939788

27. Cox AL, Mosbruger T, Mao Q, Liu Z, Wang XH, Yang HC, et al. Cellular immune selection with hepatitis C virus persistence in humans. The Journal of experimental medicine. 2005; 201(11):1741–52. https://doi.org/10.1084/jem.20050121 PMID: 15939790

28. Uebelhoer L, Han JH, Callendret B, Mateu G, Shoukry NH, Hanson HL, et al. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog. 2008; 4(9):e1000143. https://doi.org/10.1371/journal.ppat.1000143 PMID: 18773115
29. Allen TM, Yu XG, Kalife ET, Reyor LL, Lichterfeld M, John M, et al. De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol. 2005; 79(20):12952–60. https://doi.org/10.1128/JVI.79.20.12952-12960.2005 PMID: 16189997

30. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology. 1999; 117(4):933–41. https://doi.org/10.1016/s0016-5085(99)70353-7 PMID: 10500077

31. Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprowicz V, Nolan BE, Streeck H, et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. The Journal of experimental medicine. 2012; 209(1):61–75. https://doi.org/10.1084/jem.20100388 PMID: 22213804

32. Chen DY, Wolski D, Aneja J, Matsubara L, Robilotti B, Hauck G, et al. Hepatitis C virus-specific CD4+ T cell phenotype and function in different infection outcomes. The Journal of clinical investigation. 2020. https://doi.org/10.1172/JCI1126277 PMID: 31904882

33. Grakoui A, Shoukry NH, Woolard DJ, Han JH, Hanson HL, Ghrayeb J, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science. 2003; 302(5645):659–62. https://doi.org/10.1126/science.1088774 PMID: 14576438

34. Lee J, Hashimoto M, Im SJ, Araki K, Jin HT, Davis CW, et al. Adenovirus Serotype 5 Vaccination Results in Suboptimal CD4 T Helper 1 Responses in Mice. J Virol. 2017; 91(5).

35. Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, et al. Hepatitis C virus clearance, reinfecion, and persistence, with insights from studies of injecting drug users: towards a vaccine. The Lancet Infectious diseases. 2012; 12(5):408–14. https://doi.org/10.1016/S1473-3099(12)70010-5 PMID: 22541630

36. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. Lancet. 2002; 359(9316):1478–83. https://doi.org/10.1016/S0140-6736(02)08435-0 PMID: 11988247

37. Ray SC, Fanning L, Wang XH, Netski DM, Kenny-Walsh E, Thomas DL. Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. The Journal of experimental medicine. 2005; 201(11):1753–9. https://doi.org/10.1084/jem.20050122 PMID: 15939791

38. Timm J, Li B, Daniels MG, Bhattacharya T, Reyor LL, Allgaier R, et al. Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology. 2007; 46(2):339–49. https://doi.org/10.1002/hep.21702 PMID: 17593151